Regeneron Says COVID-19 Monoclonal Antibody Drug Reduces Risk Of Infection By 81.6%

The Wall Street Journal (11/8, Walker, Subscription Publication) reports Regeneron Pharmaceuticals announced that its monoclonal antibody drug REGEN-COV for COVID-19 treatment continued to provide protection against the virus for eight months, and reduced...